Abstract: wherein R1, R2, R3 and R4 are selected independently from each other from —NR5R6, —NR5R6R7+, hydrogen, aryl or heteroaryl with up to 7 ring members, C1-C20-alkyl, C1-C20-alkenyl and C1-C20-alkinyl, wherein the alkyl, alkenyl and alkinyl residues can be branched, unbranched or cyclized and optionally substituted with halogen, aryl or heteroaryl with up to 7 ring members, with the proviso that at least one of the residues R1, R2, R3 and R4 are represented by —NR5R6 or —NR5R6R7; and R5, R6 and R7 are selected independently from each other from hydrogen, aryl or heteroaryl with up to 7 ring members, C1-C20-alkyl, C1-C20-alkenyl, C1-C20-alkinyl, wherein the alkyl, alkenyl and alkinyl residues can be branched, unbranched or cyclized and optionally substituted with halogen, aryl or heteroaryl with up to 7 ring members, or R5 and R6, together with the nitrogen atom, form a heterocyclic group with up to 7 ring members; for the regulation of the activity of already activat

Abstract: wherein R1, R2, R3 and R4 are selected independently from each other from —NR5R6, —NR5R6R7+, hydrogen, aryl or heteroaryl with up to 7 ring members, C1-C20-alkyl, C1-C20-alkenyl and C1-C20-alkinyl, wherein the alkyl, alkenyl and alkinyl residues can be branched, unbranched or cyclized and optionally substituted with halogen, aryl or heteroaryl with up to 7 ring members, with the proviso that at least one of the residues R1, R2, R3 and R4 are represented by —NR5R6 or —NR5R6R7; and R5, R6 and R7 are selected independently from each other from hydrogen, aryl or heteroaryl with up to 7 ring members, C1-C20-alkyl, C1-C20-alkenyl, C1-C20-alkinyl, wherein the alkyl, alkenyl and alkinyl residues can be branched, unbranched or cyclized and optionally substituted with halogen, aryl or heteroaryl with up to 7 ring members, or R5 and R6, together with the nitrogen atom, form a heterocyclic group with up to 7 ring members; for the regulation of the activity of already activ

Abstract: A nonalcoholic beverage such as table water, mineral water or the like is described. In order to develop a well-tolerated composition which can be administered easily and which permits the body to be supplied almost incidentally with a desirable dose of ubiquinone Q 10, it is provided that it comprises 10 mg/l to 500 mg/l of ubiquinone Q 10. A production process envisages dissolving ubiquinone Q 10 in a solubilizer, and adding the solution to the beverage.

Abstract: The invention relates to the use of magnesium-pyridoxal-5'-phosphate-glutaminate to prepare a pharmaceutical suitable for the reduction of LDL-bound peroxides and for the prophylaxis of vascular lesions resulting therefrom in the absence of hypercholesteraemia or hyperlipidaemia.

Abstract: The invention concerns a pharmaceutical and its use for the treatment of states of agitation and nervous dysfunctions, which comprises as active ingredients extracts of Corydalis and Eschscholtzia obtained by alcohol extraction (2.5:10), optionally together with conventional additives, the weight ratio of the extract Eschscholtzia to Corydalis being in the range from 20:1 to 1:1.